Results 1 to 10 of about 12,862 (201)
Efficacy and safety of sofosbuvir–velpatasvir and sofosbuvir–velpatasvir–voxilaprevir for hepatitis C in Korea: a Phase 3b study [PDF]
The Korean Journal of Internal Medicine, 2023 Background/Aims Despite the availability of direct-acting antivirals (DAAs) for chronic hepatitis C virus (HCV) infection in Korea, need remains for pangenotypic regimens that can be used in the presence of hepatic impairment, comorbidities, or prior ...
Jeong Heo +24 more
doaj +2 more sources
Saudi Journal of Kidney Diseases and Transplantation, 2023 Patients with end-stage renal disease (ESRD) are at an increased risk of hepatitis C virus (HCV) infection. This study evaluated the prevalence of HCV infection in patients with ESRD on maintenance hemodialysis (MHD) and studied the effectiveness of ...
Mohammad Ashraf Bhat +3 more
doaj +2 more sources
Annals of Pharmacotherapy, 2014 Each month, subscribers to The Formulary Monograph Service receive 5 to 6 well-documented monographs on drugs that are newly released or are in late phase 3 trials. The monographs are targeted to Pharmacy & Therapeutics Committees. Subscribers also receive monthly 1-page summary monographs on agents that are useful for agendas and pharmacy/nursing ...
Lucia Rose +2 more
exaly +4 more sources
Annals of Pharmacotherapy, 2015 Each month, subscribers to The Formulary Monograph Service receive 5 to 6 well-documented monographs on drugs that are newly released or are in late phase 3 trials. The monographs are targeted to Pharmacy & Therapeutics Committees. Subscribers also receive monthly 1-page summary monographs on agents that are useful for agendas and pharmacy/nursing ...
Michael A Smith, Rima A Mohammad
exaly +3 more sources
A mini-review on sofosbuvir and daclatasvir treatment in coronavirus disease 2019
New Microbes and New Infections, 2021 Sofosbuvir and daclatasvir have been used successfully since 2013 for hepatitis C treatment. It has been shown by different studies that sofosbuvir can inhibit RNA polymerase of other positive-strand RNA viruses including Flaviviridae and Togaviridae ...
M Shabani
exaly +3 more sources
The Histopathological Effect of Sofosbuvir as Compared to Sofosbuvir Combined with Ribavirin on Submandibular Salivary Glands of Adult Albino Rats (Histological and Immunofluorescent Study) [PDF]
The Egyptian Journal of Histology, 2023 Introduction: Sofosbuvir is one of the direct acting antiviral drugs (DAAs) acting on specific Hepatitis C virus (HCV) target proteins which are important for virus replication and assembly.
Alaa Shawkat, Zoba Ali, maha bashir
doaj +1 more source
Anais da Academia Brasileira de Ciências, 2021 Direct-acting antivirals have revolutionized the treatment of chronic hepatitis C. Sofosbuvir and simeprevir are prescribed worldwide. However, there is a scarcity of information regarding their genotoxicity.
CARINA S. LIBRELOTTO +4 more
doaj +1 more source
Comedications and potential drug-drug interactions with direct-acting antivirals in hepatitis C patients on hemodialysis [PDF]
Clinical and Molecular Hepatology, 2021 Background/Aims Direct‐acting antivirals (DAAs) have been approved for hepatitis C virus (HCV) treatment in patients with end-stage renal disease (ESRD) on hemodialysis.
Po-Yao Hsu +23 more
doaj +1 more source
Effect of Sofosbuvir (Sovaldi) on the Fundic Mucosa of Adult Male Albino Rats and the Possible Protective Role of Fucoidan: Histological, Histochemical, and Immunohistochemical Study [PDF]
The Egyptian Journal of Histology, 2022 Background: Sofosbuvir (SOF) is a hopeful remedy for chronic hepatitis C virus infection. However, it records some unfavorable influences on gastrointestinal tract.
Dalia Elghazouly, Rania Yassien
doaj +1 more source
Sofosbuvir and daclatasvir [PDF]
British Journal of Clinical Pharmacology, 2016 Chronic hepatitis C infection is a major cause of chronic liver disease, cirrhosis and liver cancer as well as an important indication for liver transplantation. Sofosbuvir (Sovaldi®) 1 and daclatasvir (Daklinza®) 2 are new direct acting antivirals (DAAs) with a favourable safety and tolerability profile, which have significantly changed treatment for ...
Marleen H. M. Hessel +2 more
openaire +2 more sources